2024-10-31 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis

**1. Performance vs. S&P 500:**

Eli Lilly and Co (LLY) has significantly outperformed the S&P 500 (VOO) in terms of cumulative returns.  The LLY cumulative return is 869.34%, while the S&P 500 is at 136.74%.  This difference represents a **732.6% outperformance** for LLY, placing it at the **90.96th percentile** of its historical performance relative to the S&P 500. This indicates that LLY has consistently outperformed the broader market over its history.

**2. Recent Price Action:**

* **Closing Price:** $903.58
* **Last Market:** $849.71 (indicating a recent price drop)
* **5-day Moving Average:** $897.29
* **20-day Moving Average:** $906.72
* **60-day Moving Average:** $911.72

The recent price movement suggests a **short-term downtrend** as the closing price is below all three moving averages.

**3. Technical Indicators:**

* **RSI:** 41.82 - This suggests the stock is **not oversold**. 
* **PPO:** -0.18 - This indicates a **short-term bearish trend**, as the PPO is negative.
* **Delta_Previous_Relative_Divergence:** 1.82 (+) - This indicates a **short-term upward trend**.
* **Expected Return:** 48.57% - This represents a **high expected return** for a long-term investment in LLY, indicating a potential for significant outperformance over the S&P 500.

**4. Recent Earnings and Outlook:**

| Date       | EPS    | Revenue   |
|------------|--------|-----------|
| 2024-08-08 | 3.29   | 11.30 B$  |
| 2024-04-30 | 2.49   | 8.77 B$  |
| 2023-11-02 | -0.06  | 9.50 B$  |
| 2023-08-08 | 1.96   | 8.31 B$  |
| 2024-08-08 | 1.96   | 8.31 B$  |

The latest earnings for the quarter ended 2024-08-08 showed strong EPS growth (3.29) and a significant increase in revenue (11.30 B$). This indicates **positive momentum** in the company's performance. 

**5. Financial Data:**

**1) Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|-------------|-----------|---------------|
| 2024-06-30 | $11.30B  | 80.80%        |
| 2024-03-31 | $8.77B   | 80.91%        |
| 2023-12-31 | $9.35B   | 80.88%        |
| 2023-09-30 | $9.50B   | 80.42%        |
| 2023-06-30 | $8.31B   | 78.26%        |

**2) Capital and Profitability:**

| Quarter      | Equity    | ROE       |
|-------------|-----------|------------|
| 2024-06-30 | $13.56B  | 21.88%     |
| 2024-03-31 | $12.81B  | 17.51%     |
| 2023-12-31 | $10.77B  | 20.33%     |
| 2023-09-30 | $11.22B  | -0.51%     |
| 2023-06-30 | $11.06B  | 15.94%     |

The company demonstrates consistent revenue growth and strong profitability, with a high and stable profit margin.  The ROE data shows some volatility but overall demonstrates the company's ability to generate strong returns on invested capital.

**6. News and Recent Issues:**

**Recent Market Outlook:**
Recent news surrounding Eli Lilly and Co has been positive. The company's strong Q2 2024 earnings, driven by its diabetes and obesity drugs, have boosted investor confidence. The company's focus on developing innovative medications and its robust pipeline of potential treatments have contributed to its strong market position.

**Analyst Opinions:**
Analysts are generally bullish on Eli Lilly and Co. Finbold reported that the average price target for LLY is $103.61, representing a potential upside of over 14% from its current price.  Analysts highlight the company's strong growth potential, driven by its robust product pipeline and its expanding global presence.

**Performance Highlights:**
Eli Lilly and Co has consistently been recognized for its strong performance. The company has been ranked among the top pharmaceutical companies for its revenue, profitability, and innovation.  The company's commitment to research and development has led to the development of several blockbuster drugs, solidifying its position as a leading pharmaceutical player.

**7. Overall Analysis:**

Eli Lilly and Co (LLY) is a strong performer with a history of exceeding market expectations. The company has strong fundamentals, a robust financial position, and a promising outlook.  Recent earnings and analyst sentiment paint a positive picture for the future of LLY.  Although there is a recent price dip, the stock is not oversold and exhibits a positive long-term trajectory. 

**8. Recommendation:**

Given the company's strong fundamentals, positive market outlook, and high expected return, LLY is a **strong buy** for long-term investors seeking significant growth potential.  

**Disclaimer:** This is not financial advice and is for informational purposes only. Please consult with a qualified financial advisor before making any investment decisions.